Head, Department of Oncology
- Professor of Experimental Cancer Medicine
- Consultant Medical Oncologist, Oxford Cancer and Haematology Centre
My research concentrates on the development of new cancer drugs and on the treatment of melanoma and upper gastrointestinal tract cancers.
Mark Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology, consultant Medical Oncologist at the Oxford Cancer and Haematology Centre and Head of the Department of Oncology at the University of Oxford.
Mark was the Lead Cancer Clinician for the Oxford University Hospitals NHS Foundation Trust (2012 -2017) directed the Early Phase Cancer Trials Unit. He is Director of the Cancer Research UK Oxford Centre and co-leader of the Cancer Theme in the NIHR Biomedical Research Centre.
He studied medicine at Cambridge and Oxford and trained in medical oncology at the Christie Hospital. Mark has overseen the development of internationally leading melanoma and upper GI clinical research groups and establishment of portfolios of early phase radiotherapy and haematooncology trials in Oxford. He is involved in the evaluation of novel immunotherapeutics, including pre-clinical development, trial design, proof of mechanism and proof of concept.
In his role as Cancer Centre director, Mark has established a new Doctoral Training Programme, for a DPhil in Cancer Science, offering non-clinical, medical student and clinical fellowships and programmes for post-doctoral research.
Gupta A. et al, (2020), Br J Cancer, 122, 506 - 516
Fairfax BP. et al, (2020), Nat Med, 26, 193 - 199
Garbe C. et al, (2019), Eur J Cancer
Thomas A. et al, (2019), Eur J Cancer, 124, 131 - 141
Neurocognitive outcomes in a phase-3 randomised trial comparing adjuvant whole brain radiotherapy with observation after local treatment of brain metastases in patients with melanoma
Dhillon H. et al, (2019), ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 15, 99 - 100